Blackrock Neurotech is a team of the world’s leading engineers, neuroscientists, and visionaries. Our mission is simple: We want people with neurological disorders to walk, talk, see, hear, and feel again. We’re engineering the next generation of neural implants, including implantable brain-computer interface technology that restores function and independence to individuals with neurological disorders. Join us in changing lives today.
Connect with us:
Join Our Team | https://bit.ly/3bCsXRv
LinkedIn | https://bit.ly/3PfifOL
Twitter | https://bit.ly/3PfifOL
Instagram | https://bit.ly/3bMaYrW
Facebook | https://bit.ly/3JRc2av
Clinical Trials | https://bit.ly/3A8QPWm
Our site | https://blackrockneurotech.com
Additional information:
As the world leader in BCI tech, our pioneering neuroscience tools push the boundaries of research and empower innovation across more than 500+ global institutional partners, restoring function in patients suffering from neurological disease (ALS, Alzheimer’s, Parkinson’s), dysfunction (epilepsy, pain, brain trauma), and paralysis disorders. Our systems can be optimized from the ground up to handle even the most challenging applications.
Our BCI is the most sophisticated and long-tested human BCI, interfacing with the brain and empowering independence in those with paralysis & other neurological disorders since 2004. In fact, dozens of patients have used our BCI for a collective 30,000+ days to regain freedom through movement and communication. Our first commercial BCI, MoveAgain, received a Breakthrough Designation from the FDA in 2021 and is expected to be commercially available in 2023.
Join us in changing lives today.
ENABLING NEUROTECHNOLOGY
Paradromics’ Brain-Computer Interface (BCI) platform records brain activity at the highest possible resolution: the individual neuron. Our AI algorithms decode this massive amount of brain-data, enabling the seamless translation of thought into treatments.
THE MISSION
Data-driven BCI-based technologies for brain health
Our technology will help millions with unmet medical needs suffering from paralysis and movement disorders to chronic pain, addiction, depression and other mental health conditions.
ABOUT
Matt Angle Ph.D. (CEO) founded Paradromics to build a high-data-rate BCI platform capable of addressing critical unmet clinical needs. With early funding from the NIH and DARPA, the company developed its core neurotechnology and, by 2019, shifted focus to its first product: the Connexus® BCI.
Connexus is designed to restore communication through text, synthesized speech, and computer control for people with severe motor impairments, including those caused by ALS, stroke, or spinal cord injury. Backed by two FDA Breakthrough Device Designations and a successful first-in-human recording in May 2025, Paradromics is currently recruiting for the Connect-One Clinical Study to evaluate the long-term safety and participant benefits of their first product, the Connexus BCI.
Get contact details of over 700M profiles across 60M
companies – all with industry-leading accuracy. Sales and Recruiter users, try out our
Email Finder Extension.
Find business and personal emails and mobile phone numbers
with exclusive coverage across niche job titles, industries, and more
for unparalleled targeting. Also
available via our
Contact Data API.